Bright side of the dark genome: antigens for next-gen cancer vaccines
Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e014075
DOI: 10.1136/jitc-2025-014075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.04.2026. Verfasst von Xiao-Song Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA xiaosongw@pitt.edu bernard.fox@providence.org. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, the Hillman Foundation, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
The discovery of cancer’s hidden antigen landscape—comprising non-canonical ‘dark matter’ antigens—has unveiled a vast, untapped reservoir of immune targets for next-generation cancer immunotherapy. While most cancer vaccine strategies of the past decade have focused on mutation-derived neoantigens, studies applying sensitive mass spectrometry methods fail to identify the majority of predicted neoepitopes being presented by tumor human leukocyte antigen (HLA) molecules, potentially explaining negative results of several recent neoantigen vaccine trials. By contrast, peptides from non-canonical open reading frames, aberrant splice products, and non‐coding RNAs that derive from short-lived proteins (SLiPs) are readily stabilized in class I HLA, and as a consequence of frequently being undetected in the thymus, have demonstrated strong immunogenicity. Early reports suggest some non-canonical immunopeptides are shared within and sometimes across multiple cancer histologies, with early evidence that some have tumor-promoting functions. Because these SLiPs are degraded so quickly and are stabilized in HLA-I, the intact proteins are postulated to not be accessible to antigen-presenting cells and are not efficiently processed and cross-presented—positioning this ‘junk DNA’—derived antigen class as an attractive foundation for off-the-shelf vaccines. Here, we trace four phases of cancer vaccine evolution, review the technological advances that enabled the discovery of the dark immunopeptidome and discuss how these findings challenge established paradigms and reinvigorate interest in shared tumor antigens. By embracing this expanded antigenic universe, the field is poised to overcome key limitations of neoantigen-focused immunotherapy and move toward more universally effective cancer vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA xiaosongw@pitt.edu bernard.fox@providence.org.
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA xiaosongw@pitt.edu bernard.fox@providence.org.
- Department of Molecular Microbiology and Immunology, and Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Förderung
- NCI NIH HHS
- the Hillman Foundation
- Congressionally Directed Medical Research Programs
- Harder Family, Robert W. Franz, Elsie Franz Finley, Nancy Lematta, Lynn Loacker, The M. J. Murdock Charitable Trust, The Providence Portland Medical Foundation…
- MRA
- Shear Family Foundation
- NCI/NIH
Zitieren
APA
Wang, X. S., & Fox, B. A. (2026). Bright side of the dark genome: antigens for next-gen cancer vaccines. Journal for ImmunoTherapy of Cancer, 14(4), e014075. https://doi.org/10.1136/jitc-2025-014075
Vancouver
Wang XS, Fox BA. Bright side of the dark genome: antigens for next-gen cancer vaccines. Journal for ImmunoTherapy of Cancer. 2026;14(4):e014075. doi:10.1136/jitc-2025-014075
BibTeX
@article{Wang2026,
author = {Wang, Xiao-Song and Fox, Bernard A},
title = {Bright side of the dark genome: antigens for next-gen cancer vaccines},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {4},
pages = {e014075},
doi = {10.1136/jitc-2025-014075}
}
EUVIMED